Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis

BMC Public Health

David P Wilson¹  James Jansson²  Jianyun Wu²  Fakhrul M Islam² 

[1]Corner of West and Boundary Streets, Darlinghurst, Sydney, NSW, Australia

[2]The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia

关键词: Relative risk;    Meta-analysis;    Review;    Renal disease;    HIV;   

Others  :  1163741
DOI  :  10.1186/1471-2458-12-234

 received in 2011-05-04, accepted in 2012-03-23,  发布年份 2012

【 摘 要 】

Background

Antiretroviral therapy (ART) has substantially decreased mortality and HIV-related morbidity. However, other morbidities appear to be more common among PLHIV than in the general population. This study aimed to estimate the relative risk of renal disease among people living with HIV (PLHIV) compared to the HIV-uninfected population.

Methods

We conducted a systematic review and meta-analysis of relative risks of renal disease among populations of PLHIV reported in studies from the peer-reviewed literature. We searched Medline for relevant journal articles published before September 2010, yielding papers published during or after 2002. We also searched conference proceedings of the International AIDS Society (IAS) and Conference on Retroviruses and Opportunistic Infections (CROI) prior to and including 2010. Eligible studies were observational studies reporting renal disease defined as acute or chronic reduced renal function with glomerular filtration rate less than or equal to 60 ml/min/1.73 m² among HIV-positive adults. Pooled relative risks were calculated for various groupings, including class of ART drugs administered.

Results

The overall relative risk of renal disease was 3.87 (95% CI: 2.85-6.85) among HIV-infected people compared to HIV-uninfected people. The relative risk of renal disease among people with late-stage HIV infection (AIDS) was 3.32 (1.86-5.93) compared to other PLHIV. The relative risk of renal disease among PLHIV who were receiving antiretroviral therapy (ART) was 0.54 (0.29-0.99) compared to treatment-naïve PLHIV; the relative risk of renal disease among PLHIV who were treated with tenofovir was 1.56 (0.83-2.93) compared to PLHIV who were treated with non-tenofovir therapy. The risk of renal disease was also found to significantly increase with age.

Conclusion

PLHIV are at increased risk of renal disease, with greater risk at later stages of infection and at older ages. ART prolongs survival and decreases the risk of renal disease. However, less reduction in renal disease risk occurs for Tenofovir-containing ART than for other regimens.

【 授权许可】

   
2012 Islam et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Meguid El Nahas A, Bello AK: Chronic kidney disease: the global challenge. Lancet 2005, 365(9456):331-40.
• [2]Ibrahim F, et al.: Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS 2010, 24(14):2239-2244.
• [3]Horberg M, et al.: Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010, 53(1):62-69.
• [4]Crane HM, et al.: Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007, 21(11):1431-1439.
• [5]Bailie GR, Uhlig K, Levey AS: Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease. Pharmacotherapy 2005, 25(4):491-502.
• [6]Hogg RJ, et al.: National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003, 111(6 Pt 1):1416-1421.
• [7]Deti E, et al.: Chronic Renal Failure in HIV-Infected Patients: Incidence and Risk Factors (ANRS CO3 Aquitaine Cohort, France). In 17th Conference on Retroviruses and Opportunistics Infections. San Francisco, CA.; 2010.
• [8]Atta MG, et al.: Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006, 21(10):2809-2813.
• [9]Buskin SE, et al.: Trends in nephropathy among HIV-infected patients. J Natl Med Assoc 2009, 101(12):1205-1213.
• [10]Campbell LJ, et al.: Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 2009, 10(6):329-336.
• [11]Crum-Cianflone N, et al.: Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS 2010, 24(6):353-360.
• [12]Franceschini N, et al.: Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients. J Acquir Immune Defic Syndr 2006, 42(3):368-372.
• [13]Franey C, et al.: Renal impairment in a rural African antiretroviral programme. BMC Infect Dis 2009, 9:143. BioMed Central Full Text
• [14]Ganesan A, et al.: Determinants of Incident Chronic Kidney Disease in a Cohort of HIV-infected Patients with Free Access to Care. In 17th Conference on Retroviruses and Opportunistics Infections. San Francisco; 2010.
• [15]Heffelfinger J, et al.: Renal Impairment Associated with the Use of Tenofovir. In 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; 2006.
• [16]Jacobson LP, et al.: Proteinuria among HIV-Infected HAART recipients in the multicenter AIDS cohort study (MACS). In 4th Conference on HIV Pathogenesis and Treatment and Prevention. Sydney; 2007.
• [17]Jones R, et al.: Renal Dysfunction with Tenofovir DF Containing HAART Regimens is not Observed more Frequently: a Cohort and Case Control Study in The XV International AIDS Conference. Bangkok; 2004.
• [18]Krawczyk CS, et al.: Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS 2004, 18(16):2171-2178.
• [19]Longenecker CT, et al.: HIV viremia and changes in kidney function. AIDS 2009, 23(9):1089-1096.
• [20]Lucas GM, et al.: End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007, 21(18):2435-2443.
• [21]Mocroft A, et al.: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010, 24(11):1667-1678.
• [22]Reisler R, et al.: Chronic Kidney Disease and the Use of HAART. In 12th Conference on Retroviruses and Opportunistics Infections. Boston, Massachusetts, USA; 2005.
• [23]Roe J, et al.: HIV care and the incidence of acute renal failure. Clin Infect Dis 2008, 47(2):242-249.
• [24]Szczech LA, et al.: Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002, 61(1):195-202.
• [25]Vanig T, et al.: Tenofovir (TDF) Effect on Renal Function Factoring in both MDRD-Calculated Glomerular Filtration rate (GFR) and Spot Urine Protein-to-Creatinine (UPC) Ratio in AIDS 2008 - XVII International AIDS Conference. Mexico; 2008.
• [26]Wei A, et al.: Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003, 64(4):1462-1471.
• [27]Downs SH, Black N: The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52(6):377-384.
• [28]D'Agostino RB, et al.: Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990, 9(12):1501-1515.
• [29]Lollgen H, Bockenhoff A, Knapp G: Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories. Int J Sports Med 2009, 30(3):213-224.
• [30]Bohning D, et al.: Some general points in estimating heterogeneity variance with the DerSimonian-Laird estimator. Biostatistics 2002, 3(4):445-457.
• [31]Higgins JP, et al.: Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
• [32]Egger M, et al.: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
• [33]Liberati A, et al.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009, 62(10):e1-34.
• [34]Moher D, et al.: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097.
• [35]Palella F, et al.: Proteinuria, Glomerular Filtration Rate Reductions, and Associated Factors among HIV-infected and -uninfected Men in the Multicenter AIDS Cohort Study. In 15th Conference on HIV Pathogenesis and Treatment and Prevention, Paper#973. Boston, MA, USA; 2008.
• [36]Cooper RD, et al.: Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010, 51(5):496-505.
• [37]Kalyesubula R, Perazella MA: Nephrotoxicity of HAART. AIDS Res Treat 2011, 2011:562790.
• [38]Wyatt CM, et al.: The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008, 22(14):1799-1807.